Fig. 4

KDI – Knowledge and Data Integration. Integration of heterogeneous clinical and biological/molecular data requires a powerful information system. Data integration: all data (clinical data from eCRF, biological data, including tumor microenvironment (TME) analysis using immunohistochemistry (IHC) and HPV typing and raw data from technological platforms: exome and targeted sequencing on gDNA and ctDNA, reverse phase protein analysis (RPPA)) will be integrated into KDI core system. Afterwards advanced research functionalities will enable multiple data queries. Specific bioinformatics pipelines will generate new integrative knowledge from these heterogeneous sources of data (figure adapted from Servant et al. [22])

2015 Nov 4;15:842. doi: 10.1186/s12885-015-1801-0.

From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.

Ngo C1,2, Samuels S3, Bagrintseva K1, Slocker A4, Hupé P1,5,6,7, Kenter G3, Popovic M8, Samet N9, Tresca P1, von der Leyen H10, Deutsch E4, Rouzier R1,Belin L1, Kamal M1, Scholl S11,12; RAIDs consortium http://www.raids-fp7.eu/.

Author information

Abstract

BACKGROUND:

Cervical cancer (CC) is -second to breast cancer- a dominant cause of gynecological cancer-related deaths worldwide. CC tumor biopsies and blood samples are of easy access and vital for the development of future precision medicine strategies.

DESIGN:

BIO-RAIDs is a prospective multicenter European study, presently recruiting patients in 6 EU countries. Tumor and liquid biopsies from patients with previously non-treated cervical cancer (stages IB2-IV) are collected at defined time points. Patients receive standard primary treatment according to the stage of their disease. 700 patients are planned to be enrolled. The main objectives are the discovery of -dominant molecular alterations, -signalling pathway activation, and -tumor micro-environment patterns that may predict response or resistance to treatment. An exhaustive molecular analysis is performed using 1° Next generation sequencing, 2° Reverse phase protein arrays and 3° Immuno-histochemistry.

DISCUSSION:

The clinical study BIO-RAIDs is activated in all planned countries, 170 patients have been recruited till now. This study will make an important contribution towards precision medicine treatments in cervical cancer. The results will support the development of clinical practice guidelines for cervical cancer patients to improve their prognosis and their quality of life.